Chinese biotechnology company Nona Biosciences has appointed Dr. Hongjiang Miao as Chief AI Officer to lead its AI team and advance the company's A3 (Antibody engineering × AI × Automation) strategy, further transforming Nona into an AI-driven drug discovery company.

In this role, Dr. Miao will be responsible for developing Nona's AI strategy, spearheading the deep integration of AI technologies into core processes, consolidating data resources, algorithmic models, and experimental/business workflows, establishing an AI R&D platform, and enhancing platform stability and iterative upgrades.

He will be based in Shanghai and report directly to Dr. Di Hong, Chief Executive Officer of Nona Biosciences.

Before joining Nona Biosciences, Dr. Miao served as AI CTO at Great Bay Bio and as the head of the XLab laboratory at Tianrang Intelligence.

Dr. Miao has extensive experience in AI and biocomputing, with a proven track record of building high-performing teams and delivering impactful AI technologies. Previously, under his leadership, his team developed the first high-precision 3D protein structure prediction algorithm as well as the first AIGC protein design workbench in China, making significant contributions to computational biology and AI-driven therapeutic innovation.

Dr. Miao received his bachelor's and master's degrees in mathematics and statistics from the University of Oxford. He completed his doctorate at Imperial College London under the supervision of Professor Michael J.E. Sternberg, Fellow of the Royal Society of Biology, focusing on algorithms for predicting protein structure and function.

Welcoming Dr. Miao to the team, Dr. Di Hong, CEO of Nona Biosciences, said, "Hongjiang is an exceptional leader who uniquely understands how to translate algorithmic innovation into biologics discovery. His expertise in AI and biocomputing will be highly valuable as we advance our A3 strategy and transform Nona into an AI-driven drug discovery company. I am confident that under his leadership, our AI technology will deeply integrate with our industry-leading antibody technology platforms, creating a truly synergistic loop that accelerates the delivery of innovative therapeutics."

On joining Nona Biosciences, Dr. Miao said, “Leveraging its world-class scientific team and leading innovation platform, Nona Biosciences has established integrated solutions from Idea to IND (I to I®), ranging from target validation and antibody discovery through preclinical research, and has achieved significant breakthroughs with global impact. As Chief AI Officer, I will work closely with colleagues across all departments at Nona Biosciences to advance the company's A3 strategy—comprehensively integrating cutting-edge AI technologies with the company's unique biological platforms to build an intelligent engine for drug discovery. Together, we will decode the mysteries of life through algorithms, drive precision medicine with data, and continuously deliver more valuable products and services for patients and clients."